Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets

Human Molecular Genetics

Volumn 17, Issue 9, 2008, Pages 1318-1328

  Sutton, Beth S ^a   Crosslin, David R ^a   Shah, Svati H ^a   Nelson, Sarah C ^a   Bassil, Anthony ^a   Hale, A Brent ^a   Haynes, Carol ^a   Goldschmidt Clermont, Pascal J ^b   Vance, Jeffery M ^b   Seo, David ^b   Kraus, William E ^a   Gregory, Simon G ^a   Hauser, Elizabeth R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALANINE; ARGININE; HISTIDINE; VALINE; PHOSPHOLIPASE A2; PLA2G7 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE SEVERITY; FAMILY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DATABASE; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; AORTA; GENETICS; MIDDLE AGED; RISK FACTOR; UNITED STATES;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGE OF ONSET; AGED; AORTA; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FAMILY; FEMALE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NORTH CAROLINA; PHOSPHOLIPASES A2; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 42449096420     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn020     Document Type: Article

References (46)

1. Libby, P., Ridker, P.M. and Maseri, A. (2002) Inflammation and atherosclerosis. Circuiation, 105, 1135-1143.
2. Albert, M.A., Danielson, E., Rifai, N. and Ridker, P.M. (2001) Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. J. Am. Med. Assoc., 286, 64-70.
3. Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F. and Braunwald, E. (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation, 100, 230-235.
4. Ridker, P.M., Rifai, N. and Lowenthal, S.P. (2001) Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation, 103, 1191-1193.
5. Steinberg, D. (1997) Lewis A. Conner memorial lecture - oxidative modification of LDL and atherogenesis. Circulation, 95, 1062-1071.
6. Guerra, R., Zhao, B.R., Mooser, V., Stafforini, D., Johnston, J.M. and Cohen, J.C. (1997) Determinants of plasma platelet-activating factor acetylhydrolase: Heritability and relationship to plasma lipoproteins. J. Lip. Res., 38, 2281-2288.
7. Packard, C.J., O'Reilly, D.S.J., Caslake, M.J., McMahon, A.D., Ford, I., Cooney, J., Macphee, CH., Suckling, K.E., Krishna, M., Wilkinson, F.E. et al. (2000) Lipoprotein associated phospholipase A(2) as an independent predictor of coronary heart disease. N. Engl. J. Med., 343, 1148-1155.
8. Tjoelker, L.W., Eberhardt, C., Unger, J., Letrong, H., Zimmerman, G.A., McIntyre, T.M., Stafforini, D.M., Prescott, S.M. and Gray, P.W. (1995) Plasma platelet-activating-factor acetylhydrolase is a secreted phospholipase. A(2) with a catalytic triad. J. Biol. Chem., 270 25481-25487.
9. Ballantyne, C.M., Hoogeveen, R.C., Bang, H., Coresh, J., Folsom, A.R., Heiss, G. and Sharrett, A.R. (2004) Lipoprotein-associated phospholipase A(2), high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation, 109, 837-842.
10. Winkler, K., Winkelmann, B.R., Scharnagl, H., Hoffmann, M.M., Grawitz, A.B., Nauck, M., Bohm, B.O. and Marz, W. (2005) Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors - the Ludwigshafen risk and cardiovascular health study. Circulation 111, 980-987.
11. Nair, S., Lee, Y.H., Rousseau, E., Cam, M., Tataranni, P.A., Baier, L.J., Bogardus, C. and Permana, P.A. (2005) Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians, Diabetologia 48, 1784-1788.
12. Karra, R., Vemullapalli, S., Dong, C.M., Herderickt, E.E., Song, X.H., Slosek, K., Nevins, J.R., West, M., Goldschmidt-Clermont, P.J. and Seo, D. (2005) Molecular evidence for arterial repair in atherosclerosis. Proc. Natl. Acad Sci., 102, 16789-16794.
13. Hakkinen, T., Luoma, J.S., Hiltunen, M.O., Macphee, C.H., Milliner, K.J., Patel, L., Rice, S.Q., Tew, D.G., Karkola, K. and Yla-Herttuala, S. (1999) Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol., 19 2909-2917.
14. Singh, U., Zhong, S.M., Xiong, M.M., Li, T.B., Sniderman, A. and Teng, B.B. (2004) Increased plasma non-esterified fatty-acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin. Sci., 106, 421-432.
15. Kolodgie, F., Burke, A., Skorija, K., Ladich, E., Kutys, R., Makuria, A.T. and Virmani, R. (2006) Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 26, 2523-2529.
16. Balta, G., Gurgey, A., Kudayarov, D.K., Tunc, B. and Altay, C. (2001) Evidence for the existence of the PAF acetylhydrolase mutation (Va1279Phe) in non-Japanese populations: A preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb. Res., 101, 231-234.
17. Stafforini, D.M., Satoh, K., Atkinson, D.L., Tjoelker, L.W., Eberhardt, C., Yoshida, H., Imaizumi, T., Takamatsu, S., Zimmerman, G.A., McIntyre, T.M. et al. (1996) Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J. Clin. Invest., 97, 2784-2791.
18. Ishihara, M., Iwasaki, T., Nagano, M., Ishii, J., Takano, M., Kujiraoka, T., Tsuji, M., Hattori, H. and Emi, M. (2004) Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. J. Hum. Gen., 49, 302-307.
19. Unno, N., Sakaguchi, T., Nakamura, T., Yamamoto, N., Sugatani, J., Miwa, M. and Konno, H. (2006) A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease. J. Surg. Res., 134, 36-43.
20. Ninio, E., Tregouet, D., Carrier, J.L., Stengel, D., Bickel, C., Perret, C., Rupprecht, H.J., Cambien, F., Blankenberg, S. and Tiret, L. (2004) Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum. Mol. Genet., 13, 1341-1351.
21. Liu, P.Y., Li, Y.H., Wu, H.L., Chao, T.H., Tsai, L.M., Lin, L.J., Shi, G.Y. and Chen, J.H. (2006) Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J. Thromb. Haemost., 4, 1023-1028.
22. Kruse, S., Mao, X.Q., Heinzmann, A., Blattmann, S., Roberts, M.H., Braun, S., Gao, P.S., Forster, J., Kuehr, J., Hopkin, J.M. et al. (2000) The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am. J. Hum. Genet., 66, 1522-1530.
23. Wootton, P.T.E., Stephens, J.W., Hurel, S.J., Durand, H., Cooper, J., Ninio, E., Humphries, S.E. and Talmud, P.J. (2006) Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. Atherosclerosis, 189, 149-156.
24. Xu, H., Gregory, S.G., Hauser, E.R., Stenger, J.E., Pericak-Vance, M.A., Vance, J.M., Zuchner, S. and Hauser, M.A. (2005) SNPselector: A web tool for selecting SNPs for genetic association studies. Bioinformatics 21, 4181-4186.
25. Moonesinghe, R., Khoury, M.J. and Janssens, A.C.J.W. (2007) Most published research findings are false- but a little replication goes a long way. Plos Med., 4, 218-221.
26. Abuzeid, A.M., Hawe, E., Humphries, S.E. and Talmud, P.J. (2003) Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis, 168, 293-288.
27. Wang, D., Yang, H., Quinones, M.J., Bulnes-Enriquez, I., Jimenez, X., De La, R.R., Modilevsky, T., Yu, K., Li, Y., Taylor, K.D. et al. (2005) A genome-wide scan for carotid artery intima-media thickness: The Mexican-American Coronary Artery Disease family study. Stroke, 36, 540-545.
28. Canizales-Quinteros, S., Aguilar-Salinas, C.A., Reyes-Rodriguez, E., Riba, L., Rodriguez-Torrcs, M., Ramirez-Jimenez, S., Huertas-Vazquez, A., Fragoso-Ontiveros, V., Zentella-Dehesa, A., Ventura-Gallegos, J.L. et al. (2003) Locus on chromosome 6p linked to elevated HDL cholesterol serum levels and to protection against premature atherosclerosis in a kindred with familial hypercholesterolemia. Circ. Res., 92, 569-576.
29. Francke, S., Manraj, M., Lacquemant, C., Lecoeur, C., Lepretre, F., Passa, P., Hebe, A., Corset, L., Yan, S.L., Lahmidi, S. et al. (2001) A genome-wide scan for coronary heart disease suggests in Indo- Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum. Mol. Genet., 10, 2751-2765.
30. Samani, N.J., Erdmann, J., Hall, A.S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R.J., Meitinger, T., Braund, P., Wichmann, H.E. et al. (2007) Genomewide association analysis of coronary artery disease. N. Eng. J. Med., 357, 443-453.
31. Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A. et al. (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science, 316, 1491-1493.
32. McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D.R., Hinds, D.A., Pennacchio, L.A., Tybjaerg-Hansen, A., Folsom, A.R. et al. (2007) A common allele on chromosome 9 associated with coronary heart disease. Science, 316, 1488-1491.
33. Hauser, M.A., Li, Y.J., Takeuchi, S., Walters, R., Noureddine, M., Maready, M., Darden, T., Hulette, C., Martin, E., Hauser, E. et al. (2003) Genomic convergence: Identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum. Mol. Genet., 12, 671-677.
34. Gregory, S.G., Schmidt, S., Seth, P., Oksenberg, J.R., Hart, J., Prokop, A.M., Callier, S.J., Ban, M., Goris, A., Barcellos, L.F. et al. (2007) Allelic and functional association of the interleukin 7 receptor gene a chain (IL7Ra) with multiple sclerosis. Nat. Gen., 39, 1083-1091.
35. Fortin, D.F., Califf, R.M., Pryor, D.B. and Mark, D.B. (1995) The way of the future redux. Am. J. Cardiol., 76, 1177-1182.
36. Smith, L.R., Harrell, F.E., Rankin, I.S., Califf, R.M., Pryor, D.B., Muhlbaier, L.H., Lee, K.L., Mark, D.B., Jones, R.H., Oldham, H.N. et al. (1991) Determinants of early versus late cardiac death in patients undergoing coronary-artery bypass graft-surgery. Circulation 84, 245-253.
37. Kong, D.F.; Shaw, L.K., Harrell, F.E., Muhlbaier, L.H., Lee, K.L., Califf, R.M. and Jones, R.H. (2002) Predicting survival from the coronary arteriogram: An experience-based statistical index of coronary artery disease severity. J. Am. Coll. Cardiol., 39 (Suppl A), 327A.
38. Felker, G.M., Shaw, L.K. and O'Connor, C.M. (2002) A standardized definition of ischemic cardiomyopathy for use in clinical research. J. Am. Coll. Cardiol., 39, 210-218.
39. Hauser, E.R., Mooser, V., Crossman, D.C., Haines, J.L., Jones, C.H., Winkelmann, B.R., Schmidt, S., Scott, W.K., Roses, A.D., Pericak-Vance, M.A. et al. (2003) Design of the genetics of early onset cardiovascular disease (GENECARD) study. Am. Heart J., 145, 602-613.
40. Seo, D., Wang, T., Dressman, H., Herderick, E.E., Iversen, E.S., Dong, C., Vata, K., Milano, C.A., Rigat, F., Pittman, J. et al. (2004) Gene Expression Phenotypes of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 24, 1922-1927.
41. Cornhill, J.F., Herderick, E.E. and Vince, D.G. (1995) The clinical morphology of human atherosclerotic lesions. Lessons from the PDAY Study. Pathobiological determinants of atherosclerosis in youth. Wien. Klin. Wochenschr., 107, 540-543.
42. Xu, H., Gregory, S.G., Hauser, E.R., Stenger, J.E., Pericak-Vance, M.A., Vance, J.M., Zuchner, S. and Hauser, M.A. (2005) SNPselector: A web tool for selecting SNPs for genetic association studies. BioInformatics 21, 4191-4186.
43. Abecasis, G.R. and Cookson, W.O. (2000) GOLD - graphical overview of linkage disequilibrium. BioInformatics, 16, 182-183.
44. Barrett, J.C., Fry, B., Malier, J. and Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. BioInformatics 21, 263-265.
45. Schaid, D.J., Rawland, C.M., Tines, D.E., Jacobson, R.M. and Poland, G.A. (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet., 70, 425-434.
46. Martin, E.R., Bass, M.P., Hauser, E.R. and Kaplan, N.L. (2003) Accounting for linkage in family-based tests of association with missing parental genotypes. Am. J. Hum. Genet., 73, 1016-1026.